ArticleVirchows Archiv : an international journal of pathology2026
Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
TFEB-altered renal cell carcinomas (RCCs) display a wide range of morphological features and variable immunohistochemical profiles, often overlapping with other RCC subtypes. This variability poses significant diagnostic challenges. Consequently, there is an ongoing search for reliable ancillary tests that can aid in identifying cases that warrant molecular testing. In this study, we focused on GPNMB immunohistochemistry expression in TFEB-rearranged and TFEB-amplified RCCs. A total of 25 TFEB-altered RCCs, including 16 TFEB-amplified RCCs and nine TFEB-rearranged RCCs, were included in the study. GPNMB immunohistochemistry was positive in all nine TFEB-rearranged RCCs, demonstrating strong, diffuse cytoplasmic staining. In the TFEB-amplified RCC cohort, GPNMB expression was also detected in all 16 tumors; however, the staining pattern differed from that seen in TFEB-rearranged RCCs. Diffuse staining was observed in eight tumors (50%), four of which showed variable staining intensity, while the remaining eight tumors (50%) exhibited focal GPNMB reactivity, with intervening negative areas. GPNMB was therefore positive in all 25/25 (100%) TFEB-altered RCCs by IHC, supporting its potential role as a sensitive screening marker for such RCCs. TFEB-rearranged RCCs typically exhibited strong, diffuse GPNMB immunoreactivity, whereas TFEB-amplified RCCs more often showed patchy or focal staining of lower intensity, interspersed with areas of GPNMB negativity. Variability of staining in TFEB-amplified RCCs underscores the need for cautious interpretation, particularly in limited biopsy specimens, taking into account the morphologic findings and other immunohistochemistry stains, such as Melan A and Cathepsin K.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.